OVARIAN PREDICTIVE-SRC3 

Br J Cancer. 2013 May 7. doi: 10.1038/bjc.2013.199. [Epub ahead of print]

Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance.

Palmieri C, Gojis O, Rudraraju B, Stamp-Vincent C, Wilson D, Langdon S, Gourley C, Faratian D.

Source

1] Department of Molecular and Clinical Cancer Medicine, Institute of translational Medicine, University of Liverpool,Liverpool, UK [2] Cancer Research UK Laboratories, Division of Cancer, Imperial College London, Du Cane Road, London, UK.

Abstract

Background:Steroid receptor coactivator 3 (SRC3) is an important coactivator of a number of transcription factors and is associated with a poor outcome in numerous tumours. Steroid receptor coactivator 3 is amplified in 25% of epithelial ovarian cancers (EOCs) and its expression is higher in EOCs compared with non-malignant tissue. No data is currently available with regard to the expression of SRC-3 in EOC and its influence on outcome or the efficacy of treatment.Methods:Immunohistochemistry was performed for SRC3, oestrogen receptor-α, HER2, PAX2 and PAR6, and protein expression was quantified using automated quantitative immunofluorescence (AQUA) in 471 EOCs treated between 1991 and 2006 with cytoreductive surgery followed by first-line treatment platinum-based therapy, with or without a taxane.Results:Steroid receptor coactivator 3 expression was significantly associated with advanced stage and was an independent prognostic marker. High expression of SRC3 identified patients who have a significantly poorer survival with single-agent carboplatin chemotherapy, while with carboplatin/paclitaxel treatment such a difference was not seen.Conclusion:Steroid receptor coactivator 3 is a poor prognostic factor in EOCs and appears to identify a population of patients who would benefit from the addition of taxanes to their chemotherapy regimen, due to intrinsic resistance to platinum therapy.British Journal of Cancer advance online publication 7 May 2013: doi:10.1038/bjc.2013.199 www.bjcancer.com.